Organ-Restricted Vascular Delivery of Nanoparticles for Lung Cancer Therapy

Deniz A. Bölükbas, Stefan Datz, Charlotte Meyer-Schwickerath, Carmela Morrone, Ali Doryab, Dorothee Gößl, Malamati Vreka, Lin Yang, Christian Argyo, Sabine H. van Rijt, Michael Lindner, Oliver Eickelberg, Tobias Stoeger, Otmar Schmid, Sandra Lindstedt, Georgios T. Stathopoulos, Thomas Bein, Darcy E. Wagner, Silke Meiners

Published: 1 July 2020


Nanomedicines hold immense promise for a number of devastating diseases due to the ability to custom-design both the carrier and cargo. However, their clinical implementation has been hampered by physicochemical and biological barriers and off-target deposition which impair cell specific targeting, especially in internal organs. This study reports a new delivery approach using organ-restricted vascular delivery to allow for direct administration and recirculation of stimuli-responsive nanoparticles to promote cellular uptake into an organ of interest. Using this technique, nanoparticles reach the interior of dense tumors and are selectively taken up by lung cancer cells. Importantly, this surgical approach is essential as the same nanoparticles do not reach lung tumor cells upon systemic or intratracheal administration. Organ-restricted vascular delivery thus opens up new avenues for optimized nanotherapies for cancer and other diseases.

Full Access Link: Advanced Therapeutics